To study the effects of intralesional Rose Bengal for chemoablation of metastatic melanoma. Twenty-six target lesions in 11 patients with locoregionally recurrent disease were injected with the agent PV-10 (10% w/v Rose Bengal in saline) at a dose of 0.5 ml/cc lesion volume. An additional 28 untreated lesions were observed for potential bystander effect. The treatment was well tolerated and an objective response was observed in 12 target lesions, with an additional seven lesions remaining static over at least 12 weeks of observation. In this dose-evaluation study, response rate was dose dependent, increasing to 69% after higher dose injections. Nontarget lesions exhibited a 27% objective response rate that increased to 44% in patients exhibiting a positive response of target lesions. These findings indicate that intralesional Rose Bengal is nontoxic and could benefit patients with metastatic melanoma.
aSydney Melanoma Unit, Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown
bDiscipline of Surgery, The University of Sydney, Sydney
cNewcastle Melanoma Unit, Newcastle Misericordiae Hospital, Newcastle, New South Wales, Australia
dProvectus Pharmaceuticals, Inc., Knoxville, Tennessee, USA
Correspondence to Professor John F. Thompson, MD, FRACS, FACS, Sydney Melanoma Unit, Sydney Cancer Centre, Gloucester House, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia
Tel: +61 2 9515 7185; fax: +61 2 9550 6316;
Received 18 September 2007 Accepted 30 July 2008